Race and insurance: real-world insights on CAR-T outcomes
In this issue of Blood Advances, Karmali et al1 identified the impact of racial and insurance disparities on survival outcomes in patients with diffuse large B-cell lymphoma (DLBCL)/transformed follicular lymphoma (tFL) treated with chimeric antigen receptor T-cell therapy (CAR-T) as a standard of care and in clinical trials.
Authors
- Natalie Sophia Grover (ORCID: https://orcid.org/0000-0002-1346-3157)
- Nausheen Ahmed (ORCID: https://orcid.org/0000-0003-4336-4982)
Institutions
- University of North Carolina at Chapel Hill (US)
Publication Details
- Journal
- UNC Libraries
- Published
- 2025-04-16
- DOI
- https://doi.org/10.17615/5bxa-j573
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00